Litigation Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2017)
✉ Email this page to a colleague
Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2017)
Docket | ⤷ Try a Trial | Date Filed | 2017-02-14 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | None | Referred To | |
Patents | 6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; RE41,783; RE41,956 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc.
Biologic Drugs cited in Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-07-12 | 133 | Notice of Service | Infringement of United States Patent Nos. 6,965,027 and 7,301,023 and Reissue Patent No. RE41,783 filed by C.P… D.Sc., Regarding Infringement of United States Patent No. RE41,783 and (2) Expert Report of Leonard J…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware | External link to document |
2019-07-15 | 134 | Notice of Service | Report of Bart Kahr, Ph.D., Regarding U.S. Patent No. 6,965,027; and (3) Opening Expert Report of Katherine…on the Invalidity of the Asserted Claims of U.S. Patent Nos. RE 41,783 and 7,301,023 filed by Cadila Healthcare…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware | External link to document |
2019-09-13 | 141 | Notice of Service | Regarding Validity of United States Patent Nos. RE41,783 and 6,965,027, (4) Expert Report of Christopher…Regarding Objective Indicia of Non-Obviousness of Patent No. RE41,783, (2) Expert Report of Stanley B. Cohen…Regarding Objective Indicia of Non-Obviousness of Patent Nos. RE41,783, (3) Responsive Report of Stephen…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware | External link to document |
2019-11-11 | 145 | Notice of Service | Invalidity of the Asserted Claims of U.S. Patent Nos. RE 41,783 and 7,301,023; and (5) Reply Expert Report of Ivan…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware | External link to document |
2019-12-20 | 151 | Notice of Service | Regarding Objective Indicia of Nonobviousness of Patent No. RE41,783, (3) Reply Expert Report of Stanley B. Cohen…Regarding Objective Indicia of Nonobviousness of Patent No. RE41,783 and (4) Reply Expert Report of Christopher…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware | External link to document |
2017-02-14 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,965,027 B2; 7,301,023 B2; RE41,783…February 2017 1:17-cv-00158-GJP 830 Patent None District Court, D. Delaware | External link to document | |
2018-06-27 | 78 | Complaint - Amended | four additional patents for Xeljanz® that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December…of United States Patent No. 6,965,027 (the “’027 patent”) and United States Patent No. 7,301,023 (the…expiration date for the ’027 patent as March 25, 2023 and the ’023 patent as May 23, 2022. 24…expiration date of the RE’783 patent to December 8, 2025. The ’027 Patent 25. On November ….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |